ライフサイエンスコーパス: molecular imaging

1 atial resolutions and 20 pixels/s throughput molecular imaging.

2 uorescence/scattering issues for deep tissue molecular imaging.

3 cine and the Society of Nuclear Medicine and Molecular Imaging.

4 his process an attractive target for in vivo molecular imaging.

5 with limited applications into functional or molecular imaging.

6 ning new and exciting avenues for multimodal molecular imaging.

7 the theranostic application of fluorescence molecular imaging.

8 lectrons are shown to be a powerful tool for molecular imaging.

9 ntrast agents that could be used for in vivo molecular imaging.

10 ul technique for both two-dimensional and 3D molecular imaging.

11 alidated as a clinically relevant target for molecular imaging.

12 in human embryonic stem cells for long-term molecular imaging.

13 vides a tool for spectroscopic photoacoustic molecular imaging.

14 ke it an attractive nuclide for labeling and molecular imaging.

15 f these new organic nanoparticles in in vivo molecular imaging.

16 A-positive tumor phenotypes were selected by molecular imaging.

17 of imaging agent used for both anatomic and molecular imaging.

18 ainst HER2 have been developed as probes for molecular imaging.

19 ns for tissue engineering, therapeutics, and molecular imaging.

20 leads to more controllable and convenient 3D molecular imaging.

21 n reconstructed from in situ liquid ToF-SIMS molecular imaging.

22 e describe emergent optical technologies for molecular imaging.

23 59 amino acids) protein useful as probes for molecular imaging.

24 stage fibrosis, and heterogeneity via serial molecular imaging.

25 Here we combine dynamic dopamine-sensitive molecular imaging(4) and functional magnetic resonance i

26 fibrin-targeted, near-infrared fluorescence molecular imaging agent FTP11-CyAm7 and dextranated, mac

27 injection and imaging of a positron-emitting molecular imaging agent into the submucosa of the porcin

28 as to assess (18)F-AH113804, a peptide-based molecular imaging agent with high affinity for human c-M

29 Early detection of recurrence by molecular imaging agents against therapeutically targeta

30 mutations may alter the predictive values of molecular imaging agents for endocrine therapy response.

31 h method with perspectives on the utility of molecular imaging agents for understanding the complexit

32 potential routes for self-administration of molecular imaging agents in the form of subcutaneous and

33 ment and evaluation of targeted dual-labeled molecular imaging agents while highlighting the successf

34 vy metal content associated with traditional molecular imaging agents.

35 odistribution behavior of submicron-diameter molecular imaging agents.

36 Targeted molecular imaging allows specific visualization and moni

37 f Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, Amer

38 Molecular imaging and activity-based protein profiling s

39 Using 3D in situ molecular imaging and ANN-based automatic detection of s

40 sassembly of small molecules, especially for molecular imaging and anticancer therapeutics.

41 Advances in molecular imaging and big data technology, including in

42 Here, we used a combination of molecular imaging and biochemical tools to study the pro

43 or in vivo targeting applications, including molecular imaging and cell tracking.

44 ew outlines the neuropathological, clinical, molecular imaging and cerebrospinal fluid features of th

45 le new uses of ultrasound contrast agents in molecular imaging and drug delivery, particularly for ca

46 Sophisticated diagnostics, including molecular imaging and genomic expression profiles, enabl

47 he current advent of clinical cardiovascular molecular imaging and highlight its transformative contr

48 validated against near-infrared fluorescence molecular imaging and histology using an in vitro 3-dime

49 le/near-infrared, providing a possibility of molecular imaging and pH-sensing.

50 By contributing to noninvasive molecular imaging and radioguided surgery, nuclear medic

51 ymporter (hNIS) is an established target for molecular imaging and radionuclide therapy.

52 Molecular imaging and targeted radiotherapy with radiola

53 The Society of Nuclear Medicine and Molecular Imaging and the American College of Nuclear Me

54 ant with the Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclea

55 and technology-and the practice of clinical molecular imaging and theranostics-has created a need fo

56 lly relevant and exploitable for pretargeted molecular imaging and therapy in gastric tumors.

57 eclude the use of pretargeted strategies for molecular imaging and therapy.

58 have been widely applied in the research of molecular imaging and therapy.

59 permit future in vivo tracking of EpiSCs by molecular imaging and to transfer small pharmaceutical m

60 The molecular imaging and treatment of neuroendocrine tumors

61 ture, offering possibilities for ultrasound (molecular) imaging and targeted therapies.

62 eeds for the modern practice of NM, clinical molecular imaging, and radionuclide therapy; and suggest

63 by advances in X-ray crystallography, single-molecular imaging, and theoretical models.

64 dependent handles in targeted drug delivery, molecular imaging, and therapeutic drug monitoring.

65 Here, we used combined molecular, imaging, and anatomical approaches to investi

66 To expand the capability of MRI to encompass molecular imaging applications, we introduced biorespons

67 ess many challenges associated with advanced molecular imaging applications.

68 vealed by each measure suggests a multimodal molecular imaging approach can improve tumor characteriz

69 This highly sensitive optical molecular imaging approach can profoundly impact a wide

70 This combined molecular imaging approach links vascular inflammation t

71 We report a molecular imaging approach to quantitate protein levels

72 In summary, a multimodal molecular imaging approach was used to identify the drug

73 The molecular imaging approach we developed could be transla

74 nt methods, as well as review functional and molecular imaging approaches being investigated as emerg

75 Molecular imaging approaches can detect and quantify the

76 Molecular imaging approaches for metabolic and physiolog

77 Multitracer and multimodal molecular imaging approaches may allow us to gain import

78 Consequently, molecular imaging approaches may be used in patients to

79 To this end, molecular imaging approaches using neurotransmitter-sens

80 o date, despite numerous attempts to develop molecular imaging approaches, there is still no widely-a

81 Emerging approaches with molecular imaging are also discussed as a future directi

82 four major interventional opportunities for molecular imaging are, first, to provide guidance to loc

83 , we investigated the feasibility of optical molecular imaging as a tool for evaluating the CRM direc

84 g QDs as optical probes for spatial-temporal molecular imaging at greater depth than previously possi

85 ittee of the Society of Nuclear Medicine and Molecular Imaging, based on 2007 recommendations of the

86 t the G8 can produce high-quality images for molecular imaging-based biomedical research.

87 DAPT) is a promising tracer for radionuclide molecular imaging because of its small size (6.5 kDa), w

88 As molecular imaging better delineates the state of prostat

89 The development and validation of novel molecular imaging biomarkers has the potential to improv

90 The combination of different molecular imaging biomarkers may improve the assessment

91 developments on the horizon, such as the new molecular imaging biomarkers under investigation that ca

92 Among the molecular imaging biomarkers, amyloid-PET, which assesse

93 We used noninvasive molecular imaging (blood oxygen level-dependent magnetic

94 inescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by (18)F-FD

95 d to introduce (18)F into these moieties for molecular imaging by PET, there is an urgent and unmet n

96 68 min) that is particularly well suited for molecular imaging by positron emission tomography (PET).

97 ding of disease phenotypes; and describe how molecular imaging can be integrated to personalize surve

98 In vivo molecular imaging can measure the average kinetics and m

99 Observations: Molecular imaging can provide unique information to guid

100 and subcellular ENS for cell morphogenesis, molecular imaging, cancer therapy, and other application

101 t requires further testing.Keywords: Breast, Molecular Imaging-Cancer(C) RSNA, 2020.

102 This review highlights current metabolic and molecular imaging clinical and near-clinical application

103 loped by the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network (SNMMI CTN) fo

104 red with the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network torso phantom

105 ogram of the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network.

106 iety and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical co

107 ication for a more concerted effort from the molecular imaging community into generating better under

108 efully, this agent will be the first of many molecular imaging constructs that can determine whether

109 Metabolic and molecular imaging continues to advance our understanding

110 An optical molecular imaging contrast agent that is tailored toward

111 xpanded over the years with the emergence of molecular imaging contrast agents specifically targeted

112 ork for the eventual clinical translation of molecular imaging contrast agents.

113 Molecular imaging could be used for early detection, dis

114 Molecular imaging could be used to monitor therapy respo

115 pothesized that contrast-enhanced ultrasound molecular imaging could detect myocardial inflammation a

116 evaluated according to RECIST 1.1 as well as molecular imaging criteria (European Organization for Re

117 The quantification of pulmonary molecular imaging data remains challenging because of va

118 Molecular imaging demonstrates a significantly higher me

119 onale for selecting optical technologies for molecular imaging depending on disease location, biology

120 ectives are aimed at using A9 as a probe for molecular imaging diagnostics as well as active targetin

121 it has limited applications in the field of molecular imaging due to its low sensitivity.

122 Three-dimensional (3D) molecular imaging enables the study of biological proces

123 gate the feasibility of in vivo MMP-targeted molecular imaging for detection of lung inflammation and

124 Most recently, the rapid development of molecular imaging for precision medicine has made the fi

125 Conclusion: In patients receiving molecular imaging for prostate cancer at a single U.S. t

126 novel, individualized molecule-targeted and molecular imaging-guided therapies.

127 Molecular imaging has a promising role in complementing

128 n dopaminergic transmission in this disease, molecular imaging has been used to examine multiple aspe

129 Recent developments in molecular imaging have transformed our ability to diagno

130 Molecular imaging holds great promise for precision onco

131 Optical molecular imaging holds the potential to improve cancer

132 To determine if intraoperative molecular imaging (IMI) can improve detection of maligna

133 s for OCT imaging, noninvasive and real-time molecular imaging in both living and nonviable systems a

134 Two-plex molecular imaging in combination with down-conversion Er

135 ide our opinion as to the potential roles of molecular imaging in human fibrotic diseases.

136 amer-based activatable PA probe for advanced molecular imaging in living mice.

137 Thus far, most trials of novel molecular imaging in oncology have been small, single-ce

138 We subsequently performed molecular imaging in rodents, including AD transgenic an

139 pectrometry (SIMS) is gaining popularity for molecular imaging in the life sciences because it is lab

140 We demonstrate several mechanisms for molecular imaging, including intrinsically expressed GFP

141 s in which managing clinicians would welcome molecular imaging innovations to help with decision maki

142 lds significant promise for the expansion of molecular imaging into the realm of interventional proce

143 Molecular imaging is a complementary approach that provi

144 nature of nuclear medicine (NM) and clinical molecular imaging is a key strength of the specialty, th

145 While the use of bioluminescent proteins for molecular imaging is a powerful technology to further ou

146 Molecular imaging is a promising biomedical methodology

147 Photoacoustic molecular imaging is an emerging and promising diagnosti

148 Molecular imaging is an important advancement that has b

149 At present, checkpoint-specific molecular imaging is being increasingly investigated as

150 ng of DNA molecules in disease diagnosis and molecular imaging is established.

151 Molecular imaging is indispensable for determining the f

152 Here, we show that such discrete molecular imaging is possible using DNA-PAINT (points ac

153 We included 65 studies that reported molecular imaging measures of dopamine synthesis or rele

154 ed (HP) carbon 13 ((13)C) MRI is an emerging molecular imaging method that allows rapid, noninvasive,

155 In addition, a (68)Ga-DOTATOC-based molecular-imaging method provides a tool for detection a

156 Observations: Molecular imaging methods and magnetic resonance imaging

157 Now, molecular imaging methods for the detection of myocardia

158 Other molecular imaging methods may be needed for evaluation o

159 The important insights yielded by molecular imaging (MI) into relevant biologic signatures

160 The emergence of molecular imaging (MI), championed by radiolabeled (18)F

161 an early inflammatory biomarker for several molecular imaging modalities for diagnostic purposes and

162 Advances in molecular imaging modalities have accelerated the diagno

163 e towards using the HyperCEST technique as a molecular imaging modality.

164 Therefore, a multi-modal molecular imaging (MRI & MALDI IMS) approach was employe

165 and evaluate a new radiotracer (18)F-IRS for molecular imaging mutant EGF Receptors in vitro and vivo

166 er nanoparticles (SPNs) emerge as attractive molecular imaging nanoagents in living animals because o

167 iseases are often molecularly heterogeneous, molecular imaging of a specific pathway could be used fo

168 and we capitalized on this behavior for the molecular imaging of acute inflammation, which is charac

169 he vessel wall and its proximity with blood, molecular imaging of aneurysm optimally requires highly

170 Thus, functional and molecular imaging of angiogenesis can be performed with

171 Molecular imaging of atherosclerosis by Magnetic Resonan

172 widely used clinical tool for metabolic and molecular imaging of atherosclerosis.

173 We report a method for molecular imaging of biological materials, preserved in

174 s spectrometry applications in dual polarity molecular imaging of biological samples, particularly fo

175 Three-dimensional (3D) molecular imaging of biological structures is important

176 enefit various research fields relying on 3D molecular imaging of biological structures.

177 three distinct biomedical applications: (a) molecular imaging of blood vessels, (b) tracking of nano

178 ared (NIR) fluorescent probes for use in the molecular imaging of bone repair.

179 tion (MALDI) is the method of choice for the molecular imaging of brain samples by mass spectrometry.

180 Molecular imaging of cancer biomarkers is critical for n

181 The Near-infrared Fluorescence (NIRF) molecular imaging of cancer is known to be superior in s

182 presents one of the most important tasks for molecular imaging of cancer.

183 Molecular imaging of cancers using probes specific for t

184 d anti-CD8 diabody (Cys-diabody) for in vivo molecular imaging of CD8+ cytotoxic T lymphocytes (CTLs)

185 Molecular imaging of cell death may provide a detailed r

186 There is a growing interest in molecular imaging of cell-specific lineage markers of th

187 Adoption of molecular imaging of coronary plaque into clinical pract

188 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types

189 ce sputter yield, we successfully conduct 3D molecular imaging of frozen homogenized milk and observe

190 Direct molecular imaging of glycans-the predominant biopolymers

191 Radionuclide molecular imaging of human epidermal growth factor recep

192 If validated in humans, molecular imaging of inflammation and remodeling can pot

193 l studies to investigate its application for molecular imaging of inflammation.

194 Our results show that noninvasive molecular imaging of innate immune responses can serve a

195 aced echo trains introduce a new approach to molecular imaging of J-coupled species, such as lipids,

196 800 cm(-1) ) is highly required for specific molecular imaging of living cells with high spatial reso

197 ith SWIR emission will enable ultrasensitive molecular imaging of low-copy number analytes in biospec

198 While molecular imaging of metastases has witnessed substantia

199 Molecular imaging of nanoparticle deposition may help to

200 formative survey of the current state of the molecular imaging of ovarian cancer.

201 Targeted molecular imaging of PARP using fluorescent or radiolabe

202 In vivo NIR-IIb molecular imaging of PD-L1 and CD8 revealed cytotoxic T

203 ogrammed cell death-1 ligand-1) antibody for molecular imaging of PD-L1 in a mouse model of colon can

204 Conclusion: Molecular imaging of PR expression dynamics could be a n

205 nce precision cancer medicine facilitated by molecular imaging of preclinical breast cancer models ar

206 In situ molecular imaging of protein films adsorbed on a solid s

207 Our findings provide evidence that molecular imaging of serotonin transporters could be use

208 t has become routine not only to perform sub-molecular imaging of the chemical, electronic, and elect

209 T) is a powerful analytical tool for in vivo molecular imaging of the human brain.

210 ApoE(-/-) mice on a Western diet, ultrasound molecular imaging of the thoracic aorta for VWF A1-domai

211 riants that can be exploited for noninvasive molecular imaging of this aggressive prostate cancer sub

212 , and promising developments in, the in vivo molecular imaging of tumor immune components designed to

213 The CH1055 dye also allowed targeted molecular imaging of tumours in vivo when conjugated wit

214 n: Our study demonstrates the feasibility of molecular imaging of VLA-4, as a mechanistically relevan

215 rgeting of activated platelets may allow for molecular imaging of vulnerable atherosclerotic lesions.

216 -hGTS13-isomer2 is a new PET radiotracer for molecular imaging of x(C) (-) activity that may provide

217 d genetically encoded reporters suitable for molecular imaging or cell tracking.

218 rch fellowships to deepen their expertise in molecular imaging or targeted therapy.

219 tween the IC1 and IC2 for all functional and molecular imaging parameters, indicating that most biolo

220 t-lived isotopes (18)F and (68)Ga, excellent molecular imaging performance is achieved.

221 Keywords: Breast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/C

222 e current relationship between genotypes and molecular imaging phenotypes.

223 Molecular imaging plays an important role in detection a

224 NIR-II photoacoustic (PA) molecular imaging (PMI) is emerging as a promising new s

225 not only provide a ratiometric photoacoustic molecular imaging probe for the detection of metal ions

226 Here we review the development of novel molecular imaging probes and combinations of probes to g

227 d in mice using fluorine-18 labelled glucose molecular imaging probes and non-invasive positron emiss

228 Here we review currently available molecular imaging probes for detecting fibrosis and fibr

229 ghly two-thirds of the body, but delivery of molecular imaging probes to these spaces can be challeng

230 briefly review animal imaging technology and molecular imaging probes together with selected applicat

231 Advances in precision molecular imaging promise to transform our ability to de

232 to determine the impact of these changes on molecular imaging PSMA (miPSMA) scoring.

233 ith in vivo inflammatory changes detected at molecular imaging (r = 0.64, P = .0099).

234 Here, we report molecular imaging reactive oxygen and nitrogen species (

235 d monitor molecular processes within tumors, molecular imaging represents a fundamental tool for canc

236 Molecular imaging revealed intense lung inflammation coi

237 In this "Focus on Molecular Imaging" review, we seek to provide a brief ye

238 Molecular imaging showed increased calcium signal intens

239 In contrast, contrast-enhanced ultrasound molecular imaging showed increased signals for all targe

240 f the specific substrate responsible for the molecular imaging signal.

241 age-Guided Surgery, and members of the World Molecular Imaging Society, which discussed consensus met

242 Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) crit

243 edicine (EANM) criteria, the Prostate Cancer Molecular Imaging Standardized Evaluation criteria, and

244 Here, we report a molecular imaging strategy to potentially improve diagno

245 receptor (PRLR), forming the basis of a new molecular imaging strategy.

246 rlooked prerequisite to successfully perform molecular imaging studies in vivo by PET.

247 cological, functional magnetic resonance and molecular imaging studies of dopamine function in bipola

248 mitters for labeling bioactive molecules for molecular imaging studies.

249 graphy (PET/CT) has also identified distinct molecular imaging subtypes, including those with increas

250 Advanced molecular imaging, such as iron oxide nanoparticle imagi

251 ates the potential of (15) N2 -diazirines as molecular imaging tags for biomedical applications.

252 sing peptide receptors (GRPRs) are potential molecular imaging targets in a variety of tumors.

253 echanisms and potential myocardial viability molecular imaging targets in acute and chronic ischemia,

254 compared with MRI in the acute setting, this molecular imaging technique may be better positioned as

255 gation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to a

256 Molecular imaging techniques capable of detecting such c

257 his focus review describes the metabolic and molecular imaging techniques currently available for cli

258 New magnetic resonance (MR) molecular imaging techniques offer the potential for non

259 Novel multimodal molecular imaging techniques reveal the potential of thr

260 RI, CT, and bone scan findings, but advanced molecular imaging techniques, especially prostate-specif

261 Noninvasive molecular imaging techniques, such as SPECT and PET, pro

262 Developments in molecular imaging technologies and percutaneous biopsy t

263 Multimodal imaging based on molecular imaging technologies provides a practical meth

264 Purpose To evaluate whether noninvasive molecular imaging technologies targeting myeloperoxidase

265 Positron emission tomography (PET) is a molecular imaging technology that provides quantitative

266 oreover, emerging data suggest a promise for molecular imaging that can visualize the specific target

267 Clinicians want molecular imaging that-by being more reliable in tailori

268 the emerging field of oncological ultrasound molecular imaging, the recent significant advancements i

269 We propose a molecular imaging TNM system (miTNM, version 1.0) as a s

270 ent nuclear medicine physicians applying the molecular imaging TNM system PROMISE.

271 ent nuclear medicine physicians applying the molecular imaging TNM system PROMISE.

272 and explores the potential for metabolic and molecular imaging to affect patient-level risk predictio

273 Molecular imaging to preselect at-risk LNs may thus allo

274 his study used nanoparticle-enhanced optical molecular imaging to probe in vivo mechanisms involving

275 Our work demonstrated a powerful molecular imaging tool that can be used for high resolut

276 tudies that may lead to a broadly applicable molecular imaging tool to examine abnormal tryptophan me

277 LIP-targeted therapy can be predicted with a molecular imaging tool.

278 Here, we are aimed at developing molecular imaging tools for visualizing gamma-secretase.

279 activity of cancer immunotherapy with novel molecular imaging tools such as (89)Zr-Df-IAB22M2C for P

280 Radiolabeled molecular imaging tracers directed toward cellular targe

281 Optical molecular imaging using fluorescently labeled monoclonal

282 n-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with (68)Ga-labeled prost

283 f moving organs and contrast agent kinetics, molecular imaging using targeted and genetically express

284 first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ova

285 Baseline (18)F-FDG along with SSTR molecular imaging was useful for stratifying G3 NEN pati

286 Using functional molecular imaging, we observe that navigation in virtual

287 Here we demonstrate a concept for molecular imaging which bypasses the need for convention

288 wledge, this is the first report to describe molecular imaging with an LED-based photoacoustic scanne

289 Molecular imaging with anti-HER2 probes allows the nonin

290 for simultaneously volumetric structural and molecular imaging with cellular resolution in all three

291 ing modalities, including whole-body MRI and molecular imaging with combined PET and CT and combined

292 ce a hematological assay based on label-free molecular imaging with deep-ultraviolet microscopy that

293 Noninvasive in vivo molecular imaging with multispectral optoacoustic tomogr

294 Molecular imaging with PET is a rapidly emerging techniq

295 mild conditions for eventual application in molecular imaging with positron emission tomography (PET

296 potential for preparing new radiotracers for molecular imaging with positron emission tomography.

297 Molecular imaging with recently developed radiolabeled C

298 Molecular imaging with TCP-1 probes appears promising to

299 strands have paved the way for cellular and molecular imaging with the ability of single-molecule sw

300 The use of targeted molecular imaging would help identify patients who will